Recently, Frontier Biopharmaceutical (Nanjing) Co., Ltd. announced that it has officially launched the world's first long-acting HIV-1 fusion inhibitor, Aiboweitai.
It is understood that Aikening is China's first original anti-Ai Xin drug, with global intellectual property rights. It was approved by the State Drug Administration in June this year for "combination with other antiretroviral drugs, treatment of antiviral drugs. Treatment of HIV-1 infected individuals with viral replication".
According to the interim data of the clinical phase III trial, weekly injection of icokonin combined with lopinavir/ritonavir (two drug combination, experimental group) for the treatment of "first-line formula failure of HIV-1 infected patients", The efficacy was comparable to or better than the second-line formula recommended by the World Health Organization (WHO) (three drug combinations, control group). Significantly better renal safety compared to the control group containing tenofovir. Akonin has a new molecular mechanism of action, is effective against the popular HIV-1 virus and drug-resistant virus, and has the characteristics of low frequency of drug use (once a week), high drug resistance barrier, high safety, and small side effects. Improve the compliance of patients with medication.
AIDS has become a major public health problem facing the world. From the perspective of China, from 2010 to 2017, the number of AIDS epidemics and deaths in China has been on the rise. The National Health and Health Commission issued a statistical bulletin on the development of China's health and health undertakings. It shows that the number of AIDS cases in 2017 was 57,194, and the number of deaths was 15,251, ranking first in the national Class A and B infectious diseases. The number of newly infected people exceeded 100,000. As of July 31, 2017, the country reported that HIV infection was now reported. 728,270 people/AIDS patients.
At present, more than 30 anti-AIDS drugs and multiple compound preparations listed in the world have only one long-acting injection. Some patients who use many drugs for a long time will inevitably develop drug resistance, which not only endangers patients' life and health, but may also cause The spread of resistant viruses.
“Ai Ning’s listing has filled several gaps in antiviral drugs in China: first, it is the world’s first long-acting HIV fusion inhibitor, opening the era of long-acting anti-AIDS drugs in China; secondly, Aiken’s new The mechanism of action is effective against known drug-resistant viruses, complements existing drug mechanisms, and can save patients' lives. Again, as an injectable peptide drug, Akonin is not affected by oral and gastrointestinal functions. Meet some of the urgent medical needs of the clinic." The main research of Aikeneng clinical trial, Wu Hao, director of the Beijing You'an Hospital Infection Center affiliated to Capital Medical University, said.
Hydroxylamine Hydrochloride Basic Information
CAS: 5470-11-1
MF: NH2OH·HCl
MW: 69.49
Gadolinium Oxide Basic Information
CAS: 12064-62-9
MF: Gd2O3
MW: 362.5
EINECS: 235-060-9
Gadolinium Oxide Chemical Properties
Melting point 2330 °C(lit.)
density 7.407 g/mL at 20 °C(lit.)
storage temp. Storage temperature: no restrictions.
form nanopowder
color White
Specific Gravity 7.407
Water Solubility insoluble
Hexamethylenetetramine Basic Information
CAS: 100-97-0
MF: C6H12N4
MW: 140.19
EINECS: 202-905-8
Hexamethylenetetramine Chemical Properties
Melting point 280 °C (subl.)(lit.)
Boiling point 246.7°C (rough estimate)
density 1.33
storage temp. Store at RT.
solubility H2O: 1 M at 20 °C, clear, colorless
form Solid
Hydroxylamine Hydrochloride,Hexamethylenetetramine,Chloro Pre Tadalafil,Isopropyl Acetoacetate,Gadolinium Oxide
Shandong YingLang Chemical Co.,Ltd , https://www.sdylhgtrade.com